RESHAPE LIFESCIENCES Financials ReShape Lifesciences OTC Markets
Equities
RSLS
US7611236032
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.09 USD | +23.84% |
|
-.--% | -.--% |
| 15/05 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 15/05 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1.948 | 2.034 | 19.83 | 29.17 | 3.259 | 4.624 |
| Enterprise Value (EV) 1 | -3.6 | -0.1329 | 30.13 | 6.68 | -0.425 | 0.4269 |
| P/E ratio | - | -0.13 x | -1.14 x | -0.33 x | -0.06 x | -0.13 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.21 x | 0.13 x | 1.76 x | 2.14 x | 0.29 x | 0.53 x |
| EV / Revenue | -5.93 x | -0.01 x | 2.67 x | 0.49 x | -0.04 x | 0.05 x |
| EV / EBITDA | 0.15 x | 0.01 x | -2.79 x | -0.28 x | 0.02 x | -0.03 x |
| EV / FCF | 0.37 x | 0.02 x | -7.37 x | -1.8 x | 0.04 x | -0.04 x |
| FCF Yield | 273% | 5,906% | -13.6% | -55.5% | 2,755% | -2,740% |
| Price to Book | - | - | 1.51 x | 0.63 x | 0.96 x | 0.88 x |
| Nbr of stocks (in thousands) | 1.27 | 7.08 | 112 | 356 | 484 | 18,518 |
| Reference price 2 | 1,530 | 287.5 | 177.5 | 82.00 | 6.740 | 0.2497 |
| Announcement Date | 16/05/19 | 30/04/20 | 11/03/21 | 08/04/22 | 17/04/23 | 01/04/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.6067 | 15.09 | 11.3 | 13.6 | 11.24 | 8.678 |
| EBITDA 1 | -23.9 | -13.18 | -10.79 | -23.5 | -24.92 | -14.48 |
| EBIT 1 | -24.34 | -14.89 | -12.46 | -25.47 | -27.08 | -14.64 |
| Operating Margin | -4,012.52% | -98.66% | -110.25% | -187.29% | -240.91% | -168.69% |
| Earnings before Tax (EBT) 1 | -38.71 | -75.1 | -21.81 | -62.04 | -46.59 | -11.34 |
| Net income 1 | -81.15 | -74.21 | -21.63 | -61.93 | -46.21 | -11.39 |
| Net margin | -13,375.68% | -491.8% | -191.43% | -455.39% | -411.16% | -131.22% |
| EPS | - | -2,146 | -156.1 | -250.2 | -108.9 | -1.912 |
| Free Cash Flow 1 | -9.813 | -7.851 | -4.089 | -3.708 | -11.71 | -11.7 |
| FCF margin | -1,617.45% | -52.03% | -36.19% | -27.26% | -104.18% | -134.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 16/05/19 | 30/04/20 | 11/03/21 | 08/04/22 | 17/04/23 | 01/04/24 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.142 | 2.44 | 2.892 | 2.798 | 3.11 | 2.287 | 2.254 | 2.155 | 1.982 | 1.944 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.805 | -8.4 | -9.376 | -11.93 | -16.65 | -5.631 | -3.976 | -3.88 | -1.895 | -2.21 |
| Operating Margin | -216.58% | -344.26% | -324.2% | -426.23% | -535.34% | -246.22% | -176.4% | -180.05% | -95.61% | -113.68% |
| Earnings before Tax (EBT) 1 | -35.59 | -8.372 | -9.567 | -12.17 | -16.48 | -2.648 | -3.489 | -3.531 | -1.667 | -2.179 |
| Net income 1 | -35.46 | -8.215 | -9.576 | -11.81 | -16.61 | -2.662 | -3.493 | -3.534 | -1.698 | -2.193 |
| Net margin | -1,128.52% | -336.68% | -331.12% | -422.12% | -534.15% | -116.4% | -154.97% | -163.99% | -85.67% | -112.81% |
| EPS 2 | -124.5 | -22.00 | -25.00 | -26.00 | -35.90 | -1.560 | -1.080 | -1.020 | - | -0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/03/22 | 23/05/22 | 15/08/22 | 14/11/22 | 17/04/23 | 15/05/23 | 07/08/23 | 08/11/23 | 01/04/24 | 15/05/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 10.3 | - | - | - |
| Net Cash position 1 | 5.55 | 2.17 | - | 22.5 | 3.68 | 4.2 |
| Leverage (Debt/EBITDA) | - | - | -0.9543 x | - | - | - |
| Free Cash Flow 1 | -9.81 | -7.85 | -4.09 | -3.71 | -11.7 | -11.7 |
| ROE (net income / shareholders' equity) | -65.3% | -266% | -112% | -205% | -193% | -221% |
| ROA (Net income/ Total Assets) | -22.5% | -21.7% | -20.3% | -34.9% | -53.2% | -83.9% |
| Assets 1 | 360 | 342.7 | 106.6 | 177.6 | 86.94 | 13.57 |
| Book Value Per Share | - | - | 117.0 | 129.0 | 7.050 | 0.2800 |
| Cash Flow per Share | - | - | 24.00 | 63.80 | 7.420 | 0.1900 |
| Capex 1 | 0.05 | 0.01 | 0.39 | 0.35 | 0.13 | 0.04 |
| Capex / Sales | 8.17% | 0.09% | 3.45% | 2.59% | 1.17% | 0.5% |
| Announcement Date | 16/05/19 | 30/04/20 | 11/03/21 | 08/04/22 | 17/04/23 | 01/04/24 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +0.59% | 207B | |
| +3.92% | 181B | |
| +30.07% | 155B | |
| +32.42% | 112B | |
| +1.98% | 64.42B | |
| +19.65% | 54.38B | |
| -1.86% | 47.43B | |
| -9.53% | 37.17B | |
| -1.28% | 34.81B |
- Stock Market
- Equities
- RSLS Stock
- RSLS Stock
- Financials ReShape Lifesciences
